Rare diseases
Investigational molecules
Locations
Study on the Safety and Effectiveness of Pembrolizumab and Tretinoin in Patients with PD-1 Refractory Melanoma
FranceStudy of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma
FranceStudy of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Advanced Non-Small Cell Lung Cancer
ItalyStudy on the Effectiveness and Safety of Pembrolizumab, Quavonlimab, and Lenvatinib for Patients with Advanced Small Cell Lung Cancer Needing Second-Line Treatment
AustriaStudy on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma
FranceStudy of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Renal Cell Carcinoma
FranceStudy on the Safety and Effectiveness of Pembrolizumab, Lenvatinib, and Quavonlimab for Patients with Advanced Melanoma with Brain Metastases
FranceStudy on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer
ItalyStudy of Pembrolizumab, Belzutifan, and Lenvatinib for Patients with Advanced Clear Cell Renal Cell Carcinoma
CroatiaStudy Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
